Viewing Study NCT06535412



Ignite Creation Date: 2024-10-26 @ 3:36 PM
Last Modification Date: 2024-10-26 @ 3:36 PM
Study NCT ID: NCT06535412
Status: NOT_YET_RECRUITING
Last Update Posted: None
First Post: 2024-07-30

Brief Title: A Study of IMC-002 for the Treatment of Active Systemic Lupus Erythematosus
Sponsor: None
Organization: None

Study Overview

Official Title: A Multi-center Randomized Double-blind Placebo Control Phase 1bII Study to Evaluate the Safety and Efficacy of IMC-002 for the Treatment of Active Systemic Lupus Erythematosus
Status: NOT_YET_RECRUITING
Status Verified Date: 2024-07
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: No
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of IMC-002 in the treatment of active SLE
Detailed Description: This is a phase IbII study including 2 stage phase Ib study to find the dose for phase II study between 08mgkg12mgkg and 16mgkg dose level Phase II study is a multi-center randomized double-blind placebo control study to evaluate the safety and efficacy of IMC-002 in active Systemic Lupus Erythematosus patients

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None